Prophylaxis with oral granisetron for acute emesis induced by moderately emetogenic chemotherapy
Hesketh, P.
Seminars in Oncology 22(4 Suppl 10): 19-23
1995
ISSN/ISBN: 0093-7754 PMID: 7570050 Document Number: 3534
The 1.0 mg twice daily oral regimen of oral granisetron is an effective and well-tolerated treatment for the prevention of acute nausea and vomiting associated with moderately emetogenic chemotherapy. At this dosage, total control of acute nausea and vomiting is seen in 50% to 60% of patients. This is comparable to the control rates noted in other studies with intravenously administered granisetron in patients who received moderately to highly emetogenic chemotherapy.
Document emailed within 1 workday
Related Documents
Burris, H.; Hesketh, P.; Cohn, J.; Moriconi, W.; Ryan, T.; Friedman, C.; Fitts, D. 1996: Efficacy and safety of oral granisetron versus oral prochlorperazine in preventing nausea and emesis in patients receiving moderately emetogenic chemotherapy Cancer Journal from Scientific American 2(2): 85-90Hesketh, P.J.; Crews, J.R.; Cohen, R.; Blackburn, L.M.; Friedman, C.J. 2000: Antiemetic efficacy of single-dose oral granisetron (1 mg vs 2 mg) with moderately emetogenic chemotherapy Cancer Journal 6(3): 157-161
Bonneterre, J.; Hecquet, B. 1994: 5-HT3 receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic chemotherapy--a randomized study European Journal of Cancer 30a(7): 1041-1042
Raynov, J.; Danon, S.; Valerianova, Z. 2002: Control of acute emesis in repeated courses of moderately emetogenic chemotherapy Journal of BUON: Official Journal of the Balkan Union of Oncology 7(1): 57-60
Smith, I.E. 1990: A comparison of two dose levels of granisetron in patients receiving moderately emetogenic cytostatic chemotherapy. the Granisetron Study Group European Journal of Cancer 26(Suppl 1): S19-S23
Lehoczky, O. 1998: Report on the antiemetic effectivity of a single 1 mg oral granisetron in moderately emetogenic chemotherapies of gynecological malignancies European Journal of Gynaecological Oncology 19(5): 449-452
Heron, J.F. 1995: Single-agent oral granisetron for the prevention of acute cisplatin-induced emesis: a double-blind, randomized comparison with granisetron plus dexamethasone and high-dose metoclopramide plus dexamethasone Seminars in Oncology 22(4 Suppl. 10): 24-30
Nukariya, N.; Nakarai, I.; Kobayashi, H.; Koizumi, W.; Komatsu, H.; Uchiyama, T.; Yamaguchi, T.; Taira, O.; Minato, K.; Futatsugi, K. 1995: A comparative study of the effect of granisetron and a combination of granisetron plus steroids on cancer chemotherapy induced emesis Gan to Kagaku Ryoho. Cancer and ChemoTherapy 22(12): 1821-1829
Chiou, T.J.; Tzeng, W.F.; Wang, W.S.; Yen, C.C.; Fan, F.S.; Liu, J.H.; Chen, P.M. 2000: Comparison of the efficacy and safety of oral granisetron plus dexamethasone with intravenous ondansetron plus dexamethasone to control nausea and vomiting induced by moderate/severe emetogenic chemotherapy Zhonghua Yi Xue Za Zhi 63(10): 729-736
Feng, F.; Zhang, P.; He, Y.; Li, Y.; Zhou, M.; Chen, G.; Li, L. 2002: Clinical comparison of the selective serotonin3 antagonists ramosetron and granisetron in treating acute chemotherapy-induced emesis, nausea and anorexia Chinese Medical Sciences Journal 17(3): 168-172
Perez, E.A.; Lembersky, B.; Kaywin, P.; Kalman, L.; Yocom, K.; Friedman, C. 1998: Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy Cancer Journal from Scientific American 4(1): 52-58
Perez, E.A.; Gandara, D.R. 1994: The clinical role of granisetron (Kytril) in the prevention of chemotherapy-induced emesis Seminars in Oncology 21(3 Suppl. 5): 15-21
Chiou, T.J.; Wei, C.H.; Hsieh, R.K.; Fan, F.S.; Liu, J.H.; Chen, P.M. 1995: Comparison of intravenous granisetron with metoclopramide in the treatment of chemotherapy-induced emesis Zhonghua Yi Xue Za Zhi 56(1): 23-30
Kurita, A.; Takashima, S.; Nakata, M.; Kubo, Y.; Saiki, T.; Ohsumi, S.; Yokoyama, N.; Tanada, M.; Takiyama, W.; Saeki, H. 1997: Granisetron versus granisetron plus methylprednisolone in the prevention of chemotherapy induced nausea and vomiting--in adjuvant chemotherapy, including CDDP against gastric cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 24(1): 49-54
Marty, M. 1990: A comparative study of the use of granisetron, a selective 5-HT3 antagonist, versus a standard anti-emetic regimen of chlorpromazine plus dexamethasone in the treatment of cytostatic-induced emesis. the Granisetron Study Group European Journal of Cancer 26(Suppl 1): S28-S32
Chang, C.S.; Chen, L.T.; Huang, S.M.; Liu, T.C.; Lin, S.F.; Chen, T.P.; Wei, T.C. 1997: Comparison of intravenous granisetron with metoclopramide plus dexamethasone in the prevention of nausea and vomiting associated with emetogenic cytotoxic chemotherapy Kaohsiung Journal of Medical Sciences 13(2): 97-102
Tabona, M.V. 1990: An overview on the use of granisetron in the treatment of emesis associated with cytostatic chemotherapy European Journal of Cancer 26(Suppl 1): S37-S44
Prentice, H.G.; Cunningham, S.; Gandhi, L.; Cunningham, J.; Collis, C.; Hamon, M.D. 1995: Granisetron in the prevention of irradiation-induced emesis Bone Marrow Transplantation 15(3): 445-448
Endo, T.; Sugawara, J.; Nemoto, M.; Minami, M.; Blower, P.R. 1998: Effects of granisetron, a selective 5-HT3 receptor antagonist, on ouabain-induced emesis in ferrets Research Communications in Molecular Pathology and Pharmacology 102(3): 227-239
Kawashima, T.; Wada, T.; Morita, N.; Okamoto, K.; Matsuhira, J.; Sakamoto, T. 1994: Clinical effects of granisetron and methylpredonisolone against delayed emesis and anorexia induced by anticancer agents Gan to Kagaku Ryoho. Cancer and ChemoTherapy 21(16): 2849-2851